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vs. CsA alone), normalized a1(I) collagen mRNA levels, andEffect of anti-transforming growth factor-b antibodies in cyclo-
attenuated CsA effects on TGF-b1, TIMP-1, and MMP-9.sporine-induced renal dysfunction.
Conclusions. In this rat model of CsA-induced nephrotoxic-Background. Several experimental and clinical studies have
ity, renal insufficiency and characteristic histologic changes areimplicated a role for transforming growth factor-b (TGF-b) in
associated with altered expression of matrix and matrix-regu-mediating the nephrotoxic effects of cyclosporine (CsA). To
lating molecules. Based on our results with a-TGF-b antibod-test this hypothesis, we administered neutralizing anti-TGF-b
ies, many but not all of these nephrotoxic effects of CsA areantibodies (a-TGF-b) in a well-described rat model of chronic
mediated by TGF-b.CsA nephrotoxicity.
Methods. We studied three groups (N 5 9 per group) of
adult, male Sprague-Dawley rats that received a low-salt diet
(0.05% sodium). Normal controls were given vehicle subcuta- One-year survival of renal allografts has improved sig-neously and an alternate-day intraperitoneal injection of 3 mg
nificantly since the introduction of cyclosporine (CsA)of nonspecific mouse IgG (MIgG) for 28 days. The CsA group
[1]; however, long-term graft loss is still significantly highreceived 15 mg/kg/day of CsA subcutaneously and 3 mg of
MIgG intraperitoneally on alternate days for 28 days. The due at least in part to chronic CsA nephrotoxicity [2].
CsA/a-TGF-b group received CsA and alternate-day a-TGF-b While acute CsA toxicity causes a reversible dose-depen-
(3 mg) for 28 days. At the end of 28 days, creatinine clearance dent impairment of renal function, long-term use of CsA
was measured by 24-hour urine collection. Histologic assess-
is often associated with patchy interstitial fibrosis, affer-ment was performed for tubulointerstitial damage and arter-
ent arteriolar hyalinosis, and tubular atrophy.iolar hyalinosis. Northern analysis was performed for a1(I)
collagen and TGF-b1 gene expression, and quantitative reverse The primary mode of chronic CsA-induced renal dis-
transcription-polymerase chain reaction was performed to mea- ease is thought to be via accumulation of extracellular
sure levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix molecules and arteriolar damage. Recent studies
TIMP-2, plasminogen activator inhibitor-1 (PAI-1), matrix
suggest that CsA nephrotoxicity is primarily associatedmetalloproteinase-2 (MMP-2), and MMP-9.
with accumulation of type I collagen in patients [3] asResults. CsA-treated rats had significantly lower creatinine
well as in rat models of CsA nephrotoxicity [4]. In addi-clearance as compared with normal controls (0.43 6 0.07 vs.
0.67 6 0.14 mL/min, P 5 0.0002), increased interstitial damage tion to stimulation of the gene expression of type I colla-
and afferent arteriolar hyalinosis (P 5 0.0001), and increased gen, it is likely that CsA may regulate various molecules
a1(I) collagen (4-fold) and TGF-b1 (2.5-fold) mRNA expres- involved in matrix degradation. Thus far, plasminogension. CsA-treated rats also had significantly increased TIMP-1
activator inhibitor-1 (PAI-1) [4] and tissue inhibitor of(7.4-fold, P , 0.001), MMP-2, and PAI-1 (all approximately
metalloproteinase-1 (TIMP-1) [5] have been found to2-fold, P , 0.02) and decreased MMP-9 (85% reduction, P ,
0.001) as compared with controls. Treatment with a-TGF-b be increased in the rat model of CsA nephrotoxicity; how-
in CsA-treated rats significantly prevented the reduction in ever, various members of the matrix metalloproteinases
creatinine clearance (0.58 6 0.03 mL/min, P 5 0.009 vs. CsA (MMPs) have not been evaluated in depth. It is likely that
alone), the increase in afferent arteriolar hyalinosis (P , 0.05
the prosclerotic cytokine transforming growth factor-b
(TGF-b) plays an important role in CsA-induced accu-
mulation of extracellular matrix protein as TGF-b hasKey words: nephrotoxicity, type I collagen, TIMP-1, matrix metallo-
proteinase, immunosuppression, kidney failure. been well characterized to stimulate matrix synthesis and
inhibit matrix degradation.
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6–8]. CsA has been shown to up-regulate TGF-b expres- received 15 mg/kg/day subcutaneously of CsA and alter-
nate-day intraperitoneal injections of monoclonal neu-sion in mouse proximal tubular cells and tubulointersti-
tralizing anti-TGF-b antibody (3 mg; kindly provided bytial fibroblasts [9]. Administration of CsA to mice [9] or
Genentech, South San Francisco, CA, USA) for 28 days.rats on a low-salt diet [4] stimulates TGF-b1 mRNA and
The antibody treatment regimen was based on priorprotein expression in kidneys prior to the development
studies in mice in which administration of 15 mg/kg re-of interstitial fibrosis. TGF-b up-regulation is also dem-
sulted in a significant reduction of circulating TGF-b1onstrated in rats with chronic rejection of transplanted
levels [15], and an alternate-day regimen was chosenkidney [7]. In patients with chronic graft dysfunction and
based on the finding that the half-life of the antibodyCsA-nephrotoxicity, there is increased renal TGF-b pro-
was approximately 24 hours (Sharma, unpublished data).duction, as assessed by immunohistochemistry [8, 10, 11].
At the end of each treatment period, the animals wereTo establish a causative role, however, an interven-
placed in metabolic cages for 24 hours for quantitativetional study that blocks the effects of TGF-b in a well-
urine collection. The following day, animals were deeplycharacterized model of CsA nephrotoxicity is required.
anesthetized with Inactin (100 mg/kg, intraperitoneally).The causative role of TGF-b in mediating CsA-induced
After a ventral midline incision, blood samples werenephrotoxic effects has been addressed thus far in two
obtained after cannulating the inferior vena cava with anprior studies. The administration of angiotensin II recep-
18-gauge needle. One kidney was removed, and the cor-tor blockers attenuates TGF-b1 expression and reduced
tex was carefully dissected from the medulla. The corticalmatrix molecule expression in rats given CsA [12]; how-
portion was snap frozen in liquid nitrogen for RNA isola-ever, there was also a reduction in blood pressure, and
tion. The remaining kidney was fixed in 10% neutral-renal function declined further in the CsA-treated rats
buffered formalin and was embedded in paraffin. Urinaryreceiving angiotensin II receptor blockers. A recent
and serum creatinine were determined by a colorimetricstudy administered anti-TGF-b (a-TGF-b) antibodies to
method (Sigma, St. Louis, MO, USA). The creatininemice given a single dose of CsA [13] and found beneficial
clearance was measured using standard formula.effects of antibody administration; however, no measure-
ment of renal function was performed in the mice. In Purification of TGF-b antibody
the present study, we administered neutralizing a-TGF-b
The monoclonal neutralizing antibody (2G7) used inin a well-described rat model of chronic CsA nephrotox-
this study is pan specific to all three mammalian isoformsicity [14] and measured parameters of renal function,
of TGF-b, and the hybridoma was provided by Dr. Brianhistology, and the expression of various matrix-regulat-
Fendly (Genentech). Unpurified antibody was generated
ing molecules. in mouse ascites (Charles River Labs). The unpurified
antibody was initially filtered and then purified using an
antibody purification system (Bio-Rad, Hercules, CA,METHODS
USA) according to manufacturers specifications. DuringAnimal model
purification, sodium azide was added to the filtrate. Two
Adult male Sprague-Dawley rats (Charles River Labs, cc of this filtrate was applied to desalting columns primed
Wilmington, MA, USA) weighing between 200 and 250 g with a binding buffer and allowed to run through to
were used for the study. The animals were housed in a remove inorganic salts present in the solution. The efflu-
temperature- and light-controlled environment and re- ent containing salt-free protein was then applied to pro-
ceived a low-salt diet (0.05% sodium; Teklad Premier, tein A columns, and the IgG-free effluent was allowed
Madison, WI, USA) with free access to water. After one to run through, while the antibody remained bound to
week on the low-salt diet, the rats were weighed and the protein A column; 10 cc of elution buffer (pH 3) was
randomly assigned to the study groups. Three groups of than used to remove the antibody from the column and
animals were used with nine animals in each group. was applied to the desalting columns, 2 cc at a time, with-
out delay. The purified antibody was finally collected by
Experimental groups running sterile phosphate-buffered saline in the columns,
Three experimental groups were studied. and the protein content was measured. The final antibody
Control. Normal controls were given vehicle (castor solution was filtered via a 2 mmol/L filter, and endotoxin
oil 1 mL/kg/day) subcutaneously and alternate-day intra- levels were below 0.03 U/mL with a limulus amebocyte
peritoneal injections of 3 mg of nonspecific mouse IgG assay (Sigma). Potency of the antibody was measured
(MIgG) for 28 days. by an in vitro bioassay with serial dilutions of the anti-
Cyclosporine A. The CsA-treated group received 15 body, as previously reported [16].
mg/kg/day of CsA in castor oil (Sandoz Research, East
TGF-b1 measurementsHanover, NJ, USA) subcutaneously and alternate-day
intraperitoneal injections of 3 mg MIgG for 28 days. Plasma samples were frozen at 2208C until assayed by
a sandwich enzyme-linked immunosorbent assay (ELISA)CsA 1 a-TGF-b. An additional CsA-treated group
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kit (Genzyme, MA, USA; R&D Systems, Minneapolis, for TGF-b1 and b-actin were already available to us [17].
Hybridization and washing were performed as pre-MN, USA) according to the manufacturer’s specifica-
tions and as previously described [16]. Acid activation viously described [18]. Exposed films were scanned with
a laser densitometer, and mRNA levels were calculatedof plasma samples was required in order to convert latent
into active TGF-b1 and to record detectable levels of relative to b-actin.
TGF-b1. Plasma samples were thawed, and 10 mL were
Quantitative reverse transcription-polymeraseadded to sample diluent and activated with 1 N HCl for
chain reaction60 minutes at 48C followed by neutralization with 1 N
NaOH. Renal tissue TGF-b1 measurements were per- Total RNA was reverse transcribed to cDNA using
the GeneAmp RNA-PCR kit (Perkin-Elmer, Norwalk,formed from 100 mg of frozen renal cortex. The tissue
was placed into 1 mL of RD-51 diluent buffer (R&D CT, USA). Amplification of the cDNAs were performed
using 10 mL of reverse transcription (RT)-reaction mixSystems), homogenized, acid activated, and measured
by ELISA. A standard curve was constructed using ultra- diluted into 40 mL of the polymerase chain reaction (PCR)
buffer containing 2.5 U of AmpliTaq DNA polymerasepure human TGF-b1 as standard. The TGF-b1 concen-
tration in samples was compared to known standards inhibited with TaqStart antibody (Clontech, Palo Alto,
CA, USA) to prevent nonspecific amplification products.and read as nanograms per milliliter. One of the aliquots
from the renal tissue homogenate was assayed for total Primers (0.15 mmol/L) for rat TIMP-1, TIMP-2, MMP-2,
MMP-9, PAI-1, and b-actin were constructed from pub-protein using a Bio-Rad protein assay kit.
lished cDNA sequences in Genebank using the Primer3
Light microscopy program from Whitehead Institute for Biomedical Re-
search (Cambridge, MA, USA) [19]. The primers wereRenal tissue samples were fixed in 10% buffered for-
malin and embedded in paraffin. Three micrometer thick produced by Genosys (The Woodlands, TX, USA) and
Life Technologies (Gaithersburg, MD, USA). All primersections were stained with periodic acid-Schiff (PAS) and
Masson’s trichrome. Assessment of chronic CsA nephro- sets spanned at least one intron according to published
gene sequences and demonstrated absence of productstoxicity was evaluated using previously described pub-
lished methods [12, 14]. The histologic findings were sub- when genomic DNA was subjected to PCR analysis with
these primers. The majority of PCR reactions were per-divided into two categories: (1) interstitial inflammation
(mononuclear infiltrates, edema, and vacuolization of formed for 3 cycles at 978C for 30 seconds, 598C for 30
seconds, 558C for 1 minute, and 728C for 30 seconds,interstitial cells) and scarring (matrix-rich expansion of
the interstitium with distortion of the tubules and thick- followed by 42 cycles of 948C for 30 seconds, 598C for
30 seconds, and 728C for seconds, plus a final 10-minuteening of tubular basement membrane); and (2) arterio-
lopathy (hyalinization and destruction of the afferent extension step at 728C. Slight changes in the annealing
temperature were sometimes necessary in order to lowerarterioles). A minimum of 10 fields at 3100 magnifica-
tion were assessed and graded in each biopsy in a blinded background and to achieve a suitable quality of DNA
for analysis. Samples were electroporesed on a 3% Nu-fashion. A semiquantitative score was used to assess
the extent of changes in each category. Tubulointerstitial sieve 3:1 agarose gel (FMC Bioproducts, Rockland, ME,
USA) and stained with ethidium bromide. Internal stan-fibrosis was estimated by counting the percentage of in-
jured areas per field and scored as follows: 0 5 less than dard RNAs for quantitative RT-PCR were constructed
using the method of Forster [20] and as previously de-5% of the area involved; 1 5 5 to 25% of areas involved;
2 5 25 to 50% of areas involved; and 3 5 more than scribed [21]. The cDNA bands observed on agarose gels
were analyzed and quantitated using the Gel Doc 100050% of areas involved. Hyalinosis of the afferent arteri-
oles was determined by counting the juxtaglomerular system and Molecular Analyst software (Bio-Rad). The
values for each PCR product were evaluated as the ratioarterioles available for examination with a minimum of
50 glomeruli per biopsy assessed: 0 5 no hyalinosis; 1 5 of internal standard/RNA band intensities versus the
concentration of internal standard RNA used. Kidneyearly hyaline changes; and 2 5 pronounced hyalinosis.
RNA concentration for a particular protein was deter-
Northern analysis mined from the graphical analysis of the data in which
the equivalence point (ratio of 1) is the point at whichRNA extraction from frozen organs was performed
as previously described with minor modifications. Total the known concentration of internal standard RNA is
equal to the concentration of the unknown tissue RNA.RNA from individual samples was electrophoresed
through a 1.2% agarose gel with 0.67 mol/L of formalde-
Statistical analyseshyde, transferred to nylon membrane by capillary blot-
ting, and ultraviolet cross-linked. The cDNA probes en- Results are expressed as means 6 SE. One-way analy-
sis of variance was used to test for differences betweencoding the a1(I) collagen was provided by Dr. Sergio
Jimenez (Thomas Jefferson University), and the probes two groups and analyzed by Student unpaired t test.
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Table 1. Weight, organ weight and TGF-b1 levels in the experimental groups
Body weight g Organ weight g
TGF-b1
Plasma Renal
Initial Final Kidney Heart ng/mL pg/mg protein
Control 22262.6 35064.9 1.1260.02 1.0960.02 65.560.4 1.0960.19
CsA 21562.6 28666.6a 0.9960.03a 0.8960.03a 62.5611.7 2.5160.32a
CsA1a-TGF-b 22062.0 30366.4a 1.0260.04 0.9960.04a 29.5615.5a,b 0.3160.12a,b
Values are mean 6 SE of 9 rats in each group. Abbreviations are: CsA, cyclosporine; a-TGF-b, anti-transforming growth factor-b antibodies.
a P , 0.05 vs. Control
b P , 0.05 vs. CsA
Bonferroni’s correction was applied for comparisons be-
tween three groups. The variability within the groups
was random. P , 0.05 was considered significant.
RESULTS
Clinical characteristics and biochemical parameters
Body weights at baseline and at end of study are pre-
sented in Table 1. There was no difference in the pre-
treatment body weight between the groups. Post-treat-
ment body weight was significantly lower in the CsA
group compared with the control group (286 6 6.6 vs.
350 6 4.9, respectively, P 5 0.001). Post-treatment body
Fig. 1. Renal function is decreased with cyclosporine A (CsA) andweight was significantly lower in the CsA/a-TGF-b attenuated by a-transforming growth factor-b (a-TGF-b) antibodies.
group as well as compared with control (303 6 6.4 vs. Creatinine clearance was measured by 24-hour urine collections in all
three groups. Creatinine clearance was reduced by 36% with CsA,350 6 4.9, respectively, P 5 0.001), but was not signifi-
whereas a-TGF-b treatment only had 13% reduction as compared withcantly different between the mean body weight of the control. N 5 9 per group, *P , 0.001 vs. control, **P , 0.02 vs. CsA.
CsA group (P 5 0.130). The kidney weights of the CsA
group were significantly lower than control (P 5 0.018),
but in the CsA/a-TGF-b group, there was only a mar-
Renal function was assessed based on creatinine clear-ginal decrease in the kidney weight as compared to con-
ance from 24-hour urine collections (Figs. 1 and 2). Thetrol (P 5 0.055). One of the nine rats in the CsA/a-TGF-b
creatinine clearance was significantly reduced by 36%group was found to have a discrete nephroblastoma in
in the CsA group as compared with control (0.43 6 0.07its right kidney. The remaining kidney appeared normal
vs. 0.67 6 0.14 mL/min, P 5 0.0002). Renal function washistologically. There were no other abnormalities found
significantly preserved in the CsA/a-TGF-b group asin other organs under gross anatomic observation. Heart
compared with the CsA group (0.58 6 0.03 mL/min, P 5weight of the CsA group was significantly less than the
0.009 vs. CsA alone).control group (P 5 0.012) and was partially attenuated by
a-TGF-b treatment (P 5 0.079 vs. control). Circulating
Light microscopylevels of TGF-b1 were not increased in CsA-treated rats
Table 2 demonstrates the effect of CsA on the devel-as compared with controls (62.5 6 11.7 vs. 65.5 6 0.4
opment of arteriolar hyalinosis and interstitial damage.ng/mL, respectively); whereas, a-TGF-b treatment sig-
By the semiquantitative scoring system described pre-nificantly lowered circulating TGF-b1 as compared with
viously in this article, the CsA group had significantlythe control or CsA groups (CsA/a-TGF-b, 29.46 vs. con-
more arteriolar hyalinosis than controls (1.20 6 0.15 vs.trol, 65.48, P 5 0.01, or vs. CsA, 62.5, P 5 0.01). Renal
0.22 6 0.60, P 5 0.001). These changes were attenuatedtissue levels of TGF-b1 were measured in all three
but not prevented with a-TGF-b treatment (0.82 6 0.10groups. In contrast to circulating levels, there was a sig-
vs. 1.2 6 0.15, CsA/a-TGF-b vs. CsA, respectively, P 5nificant increase of renal TGF-b1 protein in the CsA
0.049). A representative view of the characteristic arteri-group as compared with control (2.5 6 0.3 vs. 1.1 6 0.2
olar hyalinosis associated with CsA is shown in Figurepg/mg protein, respectively, P 5 0.001). Treatment with
2B. This lesion is inhibited with a-TGF-b treatment (Fig.a-TGF-b prevented the CsA-induced increase of renal
2C). Interstitial damage was increased with CsA (1.81 6TGF-b1 and even lowered levels below control values
(CsA/a-TGF-b 0.3 6 0.1 vs. control 1.1 6 0.2, P 5 0.003). 0.16 vs. 0.09 6 0.03, CsA vs. control, respectively, P 5
Islam et al: Anti–TGF-b antibodies and CsA nephrotoxicity502
Table 2. Semiquantitative scoring by light microscopy for arterial
hylanosis and interstitial damage in the experimental groups
Arterial hylanosis Interstitial damage
Control 0.2260.6 0.0960.03
CsA 12060.15a 1.8160.16a
CsA1a-TGF-b 0.8260.10a,b 1.5760.08a
Data are mean 6 SE.
a P , 0.05 vs. Control
b P , 0.05 vs. CsA
0.001); however, a-TGF-b treatment did not significantly
decrease the extent of interstitial damage (1.57 6 0.08 vs.
1.81 6 0.16, CsA/a-TGF-b vs. CsA, respectively, P 5
0.232).
Northern analysis
Northern analysis was performed of kidneys from the
rats in each of the three groups for type I collagen and
TGF-b1 mRNA expression (Fig. 3). Renal type I colla-
gen expression as assessed by a1(I) collagen/b-actin
mRNA ratio was dramatically increased with CsA treat-
ment (0.60 6 0.23 vs. 0.14 6 0.09, CsA vs. control, respec-
tively, P 5 0.001) and was completely reduced to control
levels with a-TGF-b antibodies (0.15 6 0.11 vs. 0.60 6
0.23, CsA/a-TGF-b vs. CsA, P 5 0.001). TGF-b1 mRNA
levels were also significantly increased in the kidneys of
CsA-treated rats (0.58 6 0.25 vs. 0.24 6 0.10, CsA vs. con-
trol, respectively, P 5 0.01). Treatment with a-TGF-b anti-
bodies attenuated CsA-induced TGF-b1 mRNA expres-
sion as compared with control (0.32 6 0.11 vs. 0.24 6
0.10, respectively, P 5 0.20), supporting a role for
involvement of a positive feedback loop regulating renal
TGF-b1 expression in CsA-induced TGF-b1 stimulation.
Quantitative RT-PCR
Quantitative RT-PCR analysis was performed in the
kidneys for members of the metalloproteinase system
(MMP-2 and MMP-9; Fig. 4), for inhibitors of metallo-
proteinases (TIMP-1 and TIMP-2), and for PAI-1 (Fig.
5). The most dramatic changes with CsA were noted in
the expression of MMP-9 (a decrease to 15% of control
values) and of TIMP-1 (7.4-fold increase). Levels of
MMP-2 and PAI-1 were slightly increased (2-fold) in
CsA-treated rats. TIMP-2 expression was not alteredFig. 2. Arteriolar hyalinosis from CsA is attenuated by a-TGF-b. Rep-
by CsA treatment. Reduction of MMP-9 by CsA wasresentative histologic sections from normal rat kidney (A), CsA-treated
rat kidney (B), and CsA/a-TGF-b–treated rat kidney (C ). As noted, partially reversed with a-TGF-b treatment (45% of con-
there is arteriolar hyalinosis of the glomerular arteriole in the CsA- trol) but not to control levels (Fig. 4). In a similar pattern,treated rat (arrow), whereas this lesion was significantly attenuated
treatment with a-TGF-b significantly reduced TIMP-1with a-TGF-b treatment. Periodic acid-Schiff–stained sections from
formalin-fixed, paraffin-embedded tissue are shown. (4.2-fold increase) as compared with CsA alone, but not
to normal levels (Fig. 5). The levels of MMP-2 and PAI-1
were not significantly affected by a-TGF-b antibodies.
DISCUSSION
In the present study, we find that CsA-treated rats
have up-regulation of renal type I collagen, TIMP-1,
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and reduced MMP-9 expression, in association with up-
regulation of TGF-b1 mRNA levels. Neutralizing TGF-b
in CsA-treated rats had a remarkable effect in preventing
type I collagen stimulation and a partial but significant
effect in restoring TIMP-1 and MMP-9 levels toward
normal. This was associated with improvement in the
histologic damage to the afferent arteriole and to overall
renal function.
The role of TGF-b in mediating CsA nephrotoxicty
has been evaluated in several prior studies. Although all
have uniformly found an increase in TGF-b1 expression
[2, 12, 13], the causative role of TGF-b has not been
established. A recent study in CsA-treated mice did show
a reversal of type I collagen and TGF-b1 up-regulation
with a single dose of a-TGF-b antibodies [13], but it is
not clear whether this reversed a short-term effect as
the mice were treated with only one dose of CsA. Our
present study in a well-described rat model of CsA neph-
rotoxicity [4, 12, 14] demonstrates that TGF-b does in-
deed play an important role in mediating several—but
not all—important effects of CsA on matrix regulation.
A dramatic effect was the normalization of type I
collagen expression. CsA stimulated type I collagen ex-
pression by fourfold, and a-TGF-b antibodies prevented
this effect completely. A similar substantial increase in
renal type I collagen mRNA expression was found by
Shihab et al [4, 12]. The beneficial effect of a-TGF-b
suggests that interstitial type I collagen production by
CsA is directly related to TGF-b. If it is assumed that
TGF-b does not play a role in the vasoconstrictive effects
of CsA, then the initiation of interstitial fibrosis is likely
due to a local paracrine effect of TGF-b to stimulate
a1(I) collagen expression. The efficacy of a-TGF-b anti-
bodies is likely due to its neutralization of locally pro-
duced active TGF-b ligand via the interruption of the
positive feedback loop regulating TGF-b production.
The role of the metalloproteinase system in CsA neph-
rotoxicity has not been clearly established. A recent
study by Duymelinck et al found that TIMP-1 and PAI-1
were strongly induced in kidneys of CsA-treated rats,
but the expression of interstitial collagenase (MMP-1)
and stromelysin was not altered [5]. A major result in our
study was the induction of TIMP-1, confirming the prior
b
Fig. 3. CsA-induced up-regulation of a1(I) collagen and TGF-b1
mRNA is significantly reduced by a-TGF-b treatment. (A) Representa-
tive Northern analysis of a1(I) collagen (upper panel), TGF-b1 (middle
panel), and b-actin (lower panel) mRNA expression in kidneys from
control rats, CsA-treated rats, and CsA/a-TGF-b treated rats. Quantita-
tive analysis from all samples tested (N 5 7 per group) demonstrated
a significant increase in the ratio of a1(I) collagen/b-actin (B) and TGF-
b1/b-actin mRNA expression (C ) as compared with the control group.
Treatment with a-TGF-b antibodies completely normalized a1(I) colla-
gen expression and attenuated the increase in TGF-b1 mRNA expres-
sion. *P , 0.05 vs. control; **P , 0.05 vs. CsA.
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Fig. 4. CsA-induced down-regulation of ma-
trix metalloprotein-9 (MMP-9) is partially
prevented by a-TGF-b treatment. Quantita-
tive RT-PCR results for MMP-2 and MMP-9
in CsA-treated rats and CsA/a-TGF-b rats
expressed as percentage of control (N 5 7
per group). There is a significant increase in
MMP-2 mRNA expression in the CsA group,
but there is no effect of a-TGF-b treatment.
In contrast, there is a marked reduction of
MMP-9 mRNA expression (15% of control
value, P , 0.001), and there is a significant, but
partial, prevention with a-TGF-b treatment
(44% of control). *P , 0.02 vs. control. **P ,
0.02 vs. CsA.
Fig. 5. a-TGF-b treatment significantly at-
tenuates the increased expression of TIMP-1,
but not PAI-1, induced by CsA. Quantitative
RT-PCR results of TIMP-1, TIMP-2, and
PAI-1 in CsA and CsA/a-TGF-b group as
compared with control values. TIMP-1 ex-
pression is increased by over 7.4-fold in CsA-
treated rats but only to 4.2-fold in CsA rats
treated with a-TGF-b. There is no effect on
TIMP-2 expression with CsA. PAI-1 is in-
creased by twofold with CsA, but not signifi-
cantly attenuated with a-TGF-b treatment.
*P , 0.02 vs. control. **P , 0.0006 vs. CsA.
study, and the marked inhibition of MMP-9. TIMP-1 et al have found mRNA levels of both types I and IV
collagen to be stimulated in CsA treated rats [12]. Basedwould lead to inhibition of the metalloproteinases de-
grading interstitial collagens. MMP-9 has been primarily on the present study and the prior studies, it is apparent
that the metalloproteinases and their inhibitors play im-thought to regulate type IV collagen [22] but also may
have activity against type I collagen [23]. It is of interest portant roles in mediating CsA-induced matrix deposi-
tion, and at least part of this effect is mediated by TGF-b.that TIMP-1 has its greatest inhibitory activity against
MMP-9 [22]. Thus, it appears CsA dramatically reduces A surprising result was that a-TGF-b had a greater
effect on reducing arteriolar hyalinosis as compared withthe functional ability of MMP-9 by both decreasing the
rate of production as well as increasing its natural inhibi- interstitial damage. Arteriolar hyalinosis induced by CsA
is a well-described but poorly characterized lesion. Al-tor, TIMP-1. It is likely that type IV collagen production
is dependent on the levels of TIMP-1 and MMP-9 and though CsA is recognized to induce arteriolar vasocon-
striction of vascular smooth muscle cells, the develop-CsA would be predicted to stimulate type IV collagen
as well as type I. In support of this reasoning, Shihab ment of arteriolar hyalinosis may be due to direct toxicity
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2. Bennett WM, Demattos A, Meyer MM, et al: Chronic cyclospo-of CsA, rather than a hemodynamic consequence. Of
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